Thermo Fishr Sci Stock Price, News & Analysis

Thermo Fisher Scientific (NYSE: TMO) will release its Q3 2022 financial results on October 26, 2022, before market opening. A conference call to discuss these results and future expectations will take place at 8:30 a.m. EDT on the same day. The company's revenue is approximately $40 billion, demonstrating its leadership in serving science across various domains including diagnostics and life sciences research. Investors can listen to the call via phone or through the company’s website.

Thermo Fisher Scientific Inc. (NYSE: TMO) has signed an eight-year virtual power purchasing agreement with Enel North America to obtain renewable energy from the Seven Cowboy wind project in western Oklahoma. This agreement will provide around 400,000 megawatt hours of renewable electricity, covering half of the company's U.S. electricity consumption. The project supports Thermo Fisher's commitment to sustainability and a net-zero value chain by 2050, following a $20 million investment in green infrastructure earlier this year.

Thermo Fisher Scientific Inc. (NYSE: TMO) will participate in the Morgan Stanley 2022 Global Healthcare Conference on September 12, 2022, at 9:55 a.m. EDT. Marc N. Casper, chairman and CEO, will present at the event. Investors can access the presentation via the company's website. The company, a leader in serving science, generates approximately $40 billion in annual revenue, empowering customers in various sectors such as life sciences and diagnostics.

Thermo Fisher Scientific and Structura Biotechnology announced a collaboration to launch the Embedded CryoSPARC Live, a software solution that integrates with Thermo Fisher's technologies.

This new software enhances cryo-electron microscopy (cryo-EM), significantly reducing data processing time from days to hours.

It offers real-time data analysis for improved 3D protein structure determination, aiming to streamline workflows for researchers and commercial users. This solution underscores Thermo Fisher's commitment to advancing cryo-EM capabilities.

Thermo Fisher Scientific reported strong second quarter results for 2022, with revenue reaching $10.97 billion, marking an 18% increase. The company achieved GAAP diluted EPS of $4.22 and adjusted EPS of $5.51. Core organic revenue growth was 13%, supported by $0.63 billion in COVID-19 testing revenue. Significant product launches included the Gibco CTS TrueCut Cas9 Protein and the Phadia 2500+ series. The company expanded its production capacity to meet rising demand in high-growth markets, contributing to a strong performance outlook.

Mercy BioAnalytics has appointed Dr. Dawn Mattoon as Chief Operating Officer, effective immediately. With a 20-year career in biotechnology, Dr. Mattoon previously led Clinical Diagnostics at Quanterix Corporation, overseeing the launch of COVID-19 tests and securing FDA Breakthrough Device designations for Alzheimer's and Multiple Sclerosis diagnostics. Her expertise will bolster Mercy's efforts in commercializing the Mercy Halo™ early cancer detection platform, which targets hard-to-detect ovarian and lung cancers. CEO Paul Blavin expressed optimism for growth under her leadership.

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.30 per share, approved by its Board of Directors on July 7, 2022. The dividend is set to be paid on October 14, 2022, to shareholders on record as of September 15, 2022. With annual revenues around $40 billion, Thermo Fisher continues to support scientific progress through innovative technologies and services.

Thermo Fisher Scientific Inc. (NYSE: TMO) will release its financial results for Q2 2022 on Thursday, July 28, 2022, before the market opens. A conference call will follow at 8:30 a.m. EDT to discuss financial performance and future expectations.

The company reported an annual revenue of approximately $40 billion, supporting various scientific endeavors globally.

Relation Therapeutics has successfully raised $25 million in a seed financing round led by DCVC and Magnetic Ventures. The new capital will help expand its platform that integrates active-graph machine learning with single-cell analysis to accelerate drug discovery, targeting diseases with limited treatment options.

Dr. David Roblin and Dr. Lindsay Edwards have joined the company as CEO and CTO, respectively. The funding aims to enhance the understanding of disease biology and improve therapeutic outcomes.